鼻アレルギ-に対するリノビン・ネビュライザ-療法--臨床的検討成績を中心に

概要

論文の詳細を見る
Linovin, a preparation of histamine-carried human gamma globulin, was nebulized for six weeks to 102 patients with nasal allergy to evaluate its clinical efficacy. The patients were divided into four treatment groups: the first group received the medicament once a week, the second and third groups, treated with the drug twice a week and received combined therapy with or without cepharanthin respectively. The highest improvement in nasal symptoms was observed in the group treated with Linovin (1/2 vial) alone twice a week. Of the 102 patients, clinical efficacy was excellent in 28 (27.5%), good or better in 77 (75.5%) and fair or better in 96 (94.1%).In particular, more improvement was found in nasal congestion compared with other drugs reported previously. The results of the treatment suggested that the drug should be administered twice a week for at least six weeks, particularly for nasal obstruction.
耳鼻咽喉科臨床学会の論文